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AbstrAct:
One of the key mechanisms of the aging process of an organism and of the dysfunctionality and 
chronic diseases related with aging is the so-called cell senescence. It implies irreversible cell cycle 
arrest that occurs in response to different forms of cellular stress. Senescent cells that accumulate over 
time are viable, subject to phenotypic changes and excrete different soluble factors, and may affect 
adjacent cells, resulting in tissue and organ function disorders.
Since old age is an important risk factor for many diseases, the interest of the scientific community is 
to reduce or avoid the effects of the aging processes. Among numerous developed therapeutic strat-
egies, the development of senotherapeutics (i.e. the targeting strategy) has a significant place and is 
based on the removal of senescent cells and the abolishment of their adverse effects. Although many 
questions are still open, based on numerous experimental studies, it is expected that the development 
of senotherapeutics will contribute to the healthy life of the elderly and the treatment of specific 
age-related diseases.
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Sažetak:
Jedan od ključnih mehanizama procesa starenja organizma i sa starenjem povezanih disfunkcional-
nosti i kroničnih bolesti je tzv. stanična senescencija (stanično starenje). Podrazumijeva  nepovratni  
zastoj staničnog ciklusa koji se javlja kao odgovor na različite oblike staničnog stresa. Senescentne 
stanice koje se tijekom vremena akumuliraju, viabilne su , podliježu fenotipskim promjenama i 
izlučuju različite topljive čimbenike, te mogu utjecati  na susjedne stanice, što rezultira poremećajem 
funkcije tkiva i organa. 
Kako je starosna dob bitan čimbenik rizika za brojne bolesti, ublažavanje  ili izbjegavanje učinaka 
procesa starenja  u fokusu je interesa znanstvene zajednice. Među brojnim terapijskim strategija-
ma koje se razvijaju, značajno mjesto zauzima razvoj senoterapeutika, odnosno strategija ciljanja , 
odnosno ukljanjanja senescentnih stanica i poništavanja njihovih nepovoljnih učinaka. Premda su još 
uvijek otvorena brojna pitanja, temeljem brojnih eksperimentalnih istraživanja očekuje se da će razvoj 
senoterapeutika doprinijeti zdravom životnom vijeku starijih osoba kao i tretmanu specifičnih bolesti 
povezanih sa starenjem.  
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introduction
The life expectancy of humans has increased significantly over 
the past few decades and the assumption is that this trend 
will continue in the future1, so the aging process will have an 
important place in biomedical research. Since many illnesses 
are associated with the aging process, it is inevitable that they 
therefore increase the cost of healthcare systems around the 
world. The common goal and the challenge of a modern society 
is to ensure healthy aging and the general well-being of people. 
According to the World Health Organization (WHO)2, healthy 
aging is defined as “the process of developing and maintaining 
the functional ability that enables wellbeing in older age”, hence 
the ability to meet basic personal needs, to grow, learn and make 
decisions, to be mobile, to build and maintain relationships, to 
contribute to society, etc.
What is really aging? Why do we become elderly? How are we 
getting older? Is aging a disease? Are the diseases associated with 
aging different from aging? Is aging really inevitable? Can the 
aging process slow down / stop, or is aging a medical-solving 
problem? These and other issues are constantly present in each 
individual’s life. Researchers from different fields of science are 
trying to answer these questions.
One of the aging definitions, which includes all others, states 
that the aging process is a “progressive, generalized impairment 
of function that results in a loss of adaptive response to stress 
and an increasing probability of death”3. Undoubtedly, the aging 
process, depending on the developmental age, is a physiological 
phenomenon with useful (transformation, adaptation) and ad-
verse consequences, it is a leading risk factor to various patholog-
ical conditions. The aging process in some organisms is faster, in 
some it is slower, but always it is characterized by a reduced body 
condition and increased risk of dying.
Aging is a multifactorial, complex process, both on a population 
and on an individual level. Mnemonically, it is well described 
by abbreviation CUPID (Cumulative, Progressive, Intrinsic, 
Deleterious)4. How aging is a complex process, shows up to now 
more than 300 evolutionary and mechanistic aging theories, 
and it is to be expected that there will be new theories. All these 
theories are trying to explain why and how organisms become 
elderly. There are different classifications of these theories, but 
in general they can be divided into a) programmed theories that 
include genetically programmed aging, among which the best 
known is the theory of replicative aging, and b) damage theory, 
with theory of free radicals as the leading theory5, 6, that includes 
accumulation of unrepaired proteins, lipids and DNA damaged 
by free radicals. The central place in this theory have the changes 
in mitochondria, organelles that are necessary for almost every 
tissue. It has been shown that mitochondria are involved in 
various aspects of aging - from the reduction of functions of 
stem cells to cell senescence7. The group of damage theory also 
includes the so-called “Inflamaging” theory, according to which 
aging is the result of a continuous low-level inflammatory process 
during human life8, 9.
Since none of the set theories of aging can clarify all aspects of 
the aging process, a new term - “deleteriome” has recently been 
introduced. This term implies a measure of the biological age of 
cells, organs or systems obtained simultaneously by measuring 
genomic, epigenetic changes, mutations, profiled metabolites 
and gene expression, which is enabled by the increase of the 
“omic” fields of research. Thus, the term “deleteriome” links the 
programmed theories and damage theories10.
The results of numerous researches in the field of aging also 
provided the basis for the development of various therapeutic 
strategies. The discovery of new compounds that would slow 
down the aging process, ie prolong the healthy life span and 
test the potential anti-aging effects of already licensed drugs in 
the center is of interest to numerous scientists. In the world, a 
growing number of drug-based companies are established based 
on one of the set different strategies11. The aim of this review is 
to nearly describe the phenomenon of cellular senescence, one 
of the supposed causes of aging, and a therapeutic strategy based 
on this phenomenon. In search of scientific and review papers 
on the PubMed free search engine, following key words were 
used: cell senescence, aging, lifespan, senotherapeutics. Articles 
published in English between 2004 and 2019 were included, and 
were selected according to relevance to the topic. 
HalmarkS of aging proceSS  
The aging process of the organism is reflected in the multiple 
anatomical and functional characteristics of organisms and 
organic systems such as cardiovascular, gastrointestinal, oropha-
ryngeal, pulmonary, nervous endocrine, skin, etc.10, 12. At the 
molecular level, there are numerous changes as aging process 
characteristics, such as: a) genomic instability due to the nu-
merous possibilities of DNA damage on the one hand (eg. free 
radicals, environmental UV-induced mutagens, chemical mod-
ifications) and  an intrinsic inefficient repair systems of nuclear 
and mitochondrial DNA, antioxidative enzymes, degradation of 
damaged DNA and proteins, programmed cell death, etc., on 
the other hand13. b) epigenetic changes such as histone mod-
ifications (eg acetylation, phosphorylation)14, methylation of 
DNA, non-coding RNAs, etc.13; c) telomeres shortening, where-
by the degree of telomeres shortening is in correlation with the 
risks of diseases associated with the aging15; d) mitochondrial 
dysfunction resulting in changes in regulation of various signal 
processes16; e) disturbance of clearance and degradation of dam-
aged protein by proteasomes or autophagy17; f ) derangement of 
pathways of nutrient recognition including factors such as IGF-
1 (Insulin like growth factor-1), mTOR (mammalian target of 
rapamycin) and NAD-dependent sirtuins18, 19, 20; g) stem cell ex-
haustion; h) reduced regeneration capacity during aging and in 
age-related diseases21; i) changed intercellular communication22; 
j) cellular senescence - one of the basic causes of aging and the 
most frequently observed hallmark of aging23 .
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cell SeneScence
Cell senescence is a phenome-
non / process involved in nor-
mal tissue homeostasis, eg. 
embryonic development and 
remodeling of tissues23, 24, and 
in various age-related patholog-
ical conditions25, and is also a 
potent anticancer mechanism, 
because it limits the replica-
tion of pre-neoplastic cells26. 
According to present knowl-
edge, cell senescence implies 
stable, irreversible stopping of 
the cell cycle and is induced by 
the activation of two tumor su-
pressor pathways: p53/p21 and 
p16INK4a/pRb (retiniblastoma 
protein)27. However, recently, 
in the scientific literature, there 
are also in vitro studies that give 
indications of the possible re-
versibility of the process of cell 
senescence or replication28, 29. As 
it is assumed for now, this could 
happen if the cells are in the ini-
tial stages of the aging process, i.e. in the state of stopping the 
cell cycle. Examinations are mostly carried out on tumor cell 
cultures and for the time being it is not clear what is happening 
in vivo, so that a further concept of irreversible cell cycle arrest 
can be considered acceptable.
The process of cell senescence may be caused by various stress-
ors, including mitochondrial dysfunction, telomeric erosion, 
DNA damage, oxidative stress and other causes. Senescent 
cells have been morphologically altered (change in volume, 
change of chromatin organization, i.e. the generation of 
Senescence-Associated Heterochromatin Foci, SAHF), have 
increased activity of senescence-associated alpha-galactosidase 
(SA-alpha-gal) and secrete a large number of proinflammatory 
cytokines, chemokines, matrix metalloproteinases, MMPs, 
various growth factors - alltogether referred as proteins secreted 
into the extracellular space, known as “secretome”. Thus, the 
so-called Senescence Associated Secretory Phenotype (SASP)28 
is created. These cells may have adverse effects on neighboring 
cells that are not in the process of senescence, and may even 
contribute to the creation of tumors and other age-related dis-
eases29, 30. However, the hallmarks of senescent cells may differ 
significantly depending on cell type, cell senescence trigger, 
expression of senescence markers, secretion of different SASP 
factors, use of different cell apoptotic pathways (Senescent Cell 
Apoptotic Patways, SCAP), etc.31, 32.
The secreted pro-inflammatory cytokines further create con-
ditions for so-called “sterile inflammation” of low level, which 
contributes to the theory of inflammatory aging i.e. “Inflam-
maging”23. In addition, the feature of these cells is the suppres-
sion of the apoptosis process33. Senescent cells are normally 
removed by neutrophils, macrophages and natural killer cells 
(NK)34. However, cells can retain such a senescent status for 
years and accumulate. Accumulated cells that are in the process 
of senescence, damage the function of certain organs, but not 
necessarily with the same degree and speed for all organs. Their 
accumulation is significantly associated with the most com-
monly occurring disease during aging, affecting the average 
lifespan35. Figure 1 shows the inductors, mediators and effects 
of senescent cells.
anti-SeneScence StrategieS
Manipulation with the aging process and attempts to prolong 
the life of a healthy life, respectively, are a permanent challenge 
for scientists - gerontologists and people in general. Significant 
correlation of the aging process with age-related diseases that are 
the leading cause of death in the world (malignant, cardiovas-
cular, neurodegenerative) is the basis of many scientific studies 
of the causes and mechanisms of the aging process as well as 
possible therapeutic approaches. It is considered that manip-
ulation with the basic mechanisms of the aging process could 
delay the appearance of various chronic diseases. In accordance 
with the various molecular characteristics of aging, such studies 
 Figure 1. Inductors, mediators and effects of senescent cells. DAMPs – Damage-Associated Molecular Pattern Proteins; 
 p53 – cellular tumor antigen p53; p21 – cyclin-dependent kinase inhibitor 1; cell-cycle inhibitor;  p16 – cyclin-depen
 dent kinase inhibitor 2A, multiple tumor suppressor 1; IL – interleukine; SCAP – Senescent Cell Apoptotic Pathways;
 SASP - Senescence Associated Secretory Phenotype. 
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include the study of therapeutic potential including antioxidants, 
telomerase-activating compounds, immunosenscent drugs, 
nutraceuticals, reprogramming of stem cells, senotherapeutics, 
autophagy induction, finding the specific presentation of ag-
ing-related diseases and integrating of numerous data obtained 
by”omics” techniques, organ transplants, treatment  with stem 
cells, or young blood/plasma rejuvenation, etc. 36, 37. Investiga-
tions of the mentioned anti-ag-
ing strategies as well as general 
research of the aging process are, 
for the time being, mostly exper-
imental in nature and are mainly 
focused on aging model systems. 
Because of moral and ethical 
principles in human studies, 
clinical research in literature is 
significantly less delineated.
The general impression is that 
scientists biogerontologists 
increasingly perceive that 
anti-aging strategies directed at 
one molecule are limited; they 
consider that the dynamic, net-
worked nature of the life process, 
which involves transformations 
and adaptations to survival and 
health, is at the same time ne-
glected. Therefore, interventions/
strategies that enhance homeody-
namics are also considered. These strategies include nutrition, 
eg. intermittent hunger, Mediterranean diet, phytochemicals, 
physical and mental activity (common term - hormesis) 38. One 
of the more common researach strategies is the development 
and application of senotherapeutics, that is the main topic of 
this review.
 
Figure 2. Positions of effects of senotherapeutics .  DAMPs – Damage-Associated Molecular Pattern Proteins; Senescence Associated 
Secretory Phenotype; SASP- Senescence Associated Secretory Phenotype. 
Compound Target / Pathway References
SENOLYTICS
ABT 737 BCL-2 family (BCL-2, BCL-XL, BCL-W) 43
ABT-263 (navitoclax) BCL-2 family (BCL-2, BCL-XL, BCL-W) 44
Dasatinib + Quercetin







Piperlongumine Multiple pathways 50
FOXO4-DRI peptide p53 / p21 / serpin 51
SENOMORFICS
NBD peptide IKK / NFB pathway 52
JAK inhibitor (ruxolitinib) JAK (Janus kynase) pathway 53
ESC-CM PDGF / FGF pathway 54
Mmu-miR-291a-3p TGFBR2 / p21 pathway 55
Table 1.  Examples of senolytics and senomorphics and their target molecules/pathways
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SenotHerapeuticS
It has been shown that accumulation of senescent cells has a 
causal role in the aging of organs and organisms, and in age-re-
lated diseases. Therefore, most therapeutic approaches to the 
slowing down of various aging phenotypes and related comor-
bidities are based on preventing the accumulation and elimina-
tion of senescent cells with so-called senoterapeutics.
The fundamental mechanisms of activity of senoterapeutics 
include a) on one hand, selective killing of senescent cells 
(senolytics), where the main goals are the biological pathways of 
cell senescence processes; b) on the other hand, the suppression 
of SASP factors (senomorphics), i.e. the prevention of possible 
pro-inflammatory effect by targeting regulators and effectors of 
SASP39, 40. For both strategies already there are convincing results 
obtained on experimental model systems. In the development 
of senoterapeutics there is also c) a strategy to stimulate the im-
mune response to the senescent cells which should result in their 
removal from the tissue41, 42.
The main positions of the activity of the senotherapeutics are 
shown schematically in Figure 2. and in Table 1. are examples of 
the group of senolitics and senomorphyc compounds, some of 
which are described in more detail below.
Within the previously mentioned strategy c) - stimulation of 
senescent cell clearance by the immune system - the most com-
monly mentioned is the potential use of anti-DPP4 (cell surface 
protein CD26 or dipeptidyl peptidase 4, DPP4) antibody56 and 
monoclonal antibody to CD957 as targets for the promotion of 
antibody-dependent cell-mediated cytotoxicity (ADDC) - de-
pendent on antibody to senescent cells.  
There are several classes of senolitics which include, for example, 
BCL-2 family proteins,  heat shock proteins (HSP90) inhibitors, 
p53 / p21 and PI3K / AKT pathways inhibitors, receptor kinase 
inhibitors, histone deacetylase (HDAC) inhibitors,  natural 
compounds, etc. Currently, the most interesting informations are 
about senolytics directed against members of the BCL-2 protein 
family, eg. BCL-W and BCL-XL58,  thus targeting the resistance 
of senescent cells to apoptosis, so that their destruction leads to 
the activation of programmed cell death59 and changes in the 
autophagy process. The first described senolytics were dasatinib 
(under the name SPRYCEL was used in the treatment of adult 
patients with chronic myeloic leukemia; its targets are several 
protein tyrosine kinases (eg. BCR/Abl c-KIT and some mem-
bers of Scr family), and herbal flavonoid quercetin involving 
the PI3K / AKT pathways as a molecular target60, 61. Dasatinib 
effectively reduces the viability of senescent cells in vitro and is 
also confirmed by its in vivo effectiveness.The combination of 
these compounds with senolytic action has also been used in 
investigations.
Navitoclax (i.e. ABT 263) is considered like senotherapeutic 
of powerul senolytic activity62. It is directed to inhibition of 
specific BCL-XL and BCL-W members of the family of BCL-2 
apoptotic proteins. Navitoclax is also used in the treatment of 
some malignant conditions62, but its use is limited due to adverse 
thrombocytopenic and neutropenic effects. Navitoclax analogs 
such as A1331852, A1155453, ABT 737 also target members of 
the BCL-2 protein family in both in vitro and in vivo models42,49.
In addition to quercetin, the therapeutic potential of other 
phytochemicals, such as flavonol fisetin and piperlongumine al-
kaloids, is also examined. The mechanism of action of the fisetin 
includes the PI3K / AKT / mTOR pathway, and the piperlong-
umine appears to include the NF-κB pathway 50. According to 
literature, these compounds also exhibit senolytic and senomor-
phic activity, depending on the type of cells used in the study49. 
Of the natural compounds in the literature are also mentioned 
flavonoids kaempferol, apigenin, some compounds from the 
polyketide group and resveratrol63.
The potential for senolytic activity is shown by inhibitors such as 
HSP90, geldanamycin, benzoquinone antineoplastic antibiotic 
and its analogs 17-AAG and 17-DMAG46, an inhibitor of inter-
actions of MDM2 / p53 proteins, as well as UBX0101, a small 
molecule that is already in phase 1 clinical trial in patients with 
osteoarthritis of the knee64. Furthermore, the senolytic activity of 
HDAC inhibitor - panobinostat, was demonstrated in senescent 
lung cancer cells and in the cell line of head and neck squamous 
cell carcinoma65. Panabinostat inhibits the interaction of FOXO4 
and p53 and induces apoptosis in the IMR9047 population, as 
well as in other types of senescent cells51.
As already mentioned, senescent cells differ regarding to their 
characteristics, in concordance to specific cellular or tissue 
factors, for example expression of different markers, secretion of 
various SASP factors, and using different SCAP pathways. There-
fore it can be assumed that other classes of senolytics will be 
discovered in the future, and that the combination of senothera-
peutics will be more acceptable for the elimination of senescent 
cells from different tissues in vivo40,46.
Initial studies with senolytics are promising but there is no doubt 
that there are still many unknowns about their effectiveness. 
According to research on the osteoarthritis model, it has been 
shown that after discontinuation of senolytics, senescent cells 
may reappear64.
A group of senotherapeutics that suppresses or modulates secre-
tory phenotypes without inducing apoptosis and in a certain way 
interferes with “inflammaging” i.e. with senoinflamamtion are 
senomorphic drugs. These are, for example, compounds targeting 
senoinflamation66, telomerase activators42, mimetics of caloric 
restriction67, activators of sirtuins68 and autophagy69, mTOR 
inhibitors70, antioxidants and other compounds. As indicated 
in Table 1, the mechanisms of the activity of the senomorphic 
drugs include inhibitors of NFκB and IκB kinase (IKK)52, Janus 
kinase pathway inhibitors (JAK)52, inhibitors of PDGF / FGF 
pathway and TGFBR2 / p21 pathway42. It has been shown that 
rapamycin, a drug currently used to suppress immunity in trans-
planted organ patients, acts as a SASP suppressant, using a mech-
anism that includes the inhibition of mTOR kinase, associated 
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with the inclusion of Nrf2-dependent and independent modules 
71. Senomorphic potential is further attributed to some herbal 
compounds such as quercetin-3-O-beta-D glucuronide, juglanin 
and quercetagetin 3,4, -dimethyl ether 72, 73, 74.
As already mentioned, one of the ways of removing senescent 
cells to maintain tissue homeostasis in physiological, patholog-
ical and aging conditions is also a cooperation with immune 
system75. As an alternative therapeutic approach to the removal 
of senescent cells, an immune therapy strategy, i.e., antibody-me-
diated targeted drug delivery to senescent cells, is also estab-
lished. It is also considered that imunotherapeutics for malignant 
diseases that are already in development could also be used for 
targeting senescent cells in the aging process and with aging-re-
lated diseases (Alzheimer’s, diabetes, pulmonary fibrosis, and 
other diseases). Expression of DPP4 on the membranes of senes-
cent fibroblast was revealed in recent studies by Kim EC. et al.42. 
Also, it was highlighted the possibility of the use of DPP4 as a 
target for the promotion of antibody-dependent cell-mediated 
cytotoxicity against senescent cells56. Another goal of the im-
munotherapy strategy is the expression of the NKG2D receptor 
(Natural killer group 2D) on senescent cells, recognized by NK 
cells that also remove them. The tumor cell removal strategies 
are also developed on this principle76.
In addition to investigations that, based on the new molecular 
knowledge of senescent cells and mechanisms of their forma-
tion, have the goal of detecting appropriate therapeutic goals, 
there is  also a recent investigation of already existing licensed 
drugs such as senolytics or senomorphic compounds. Hence, 
these drugs would have an additional purpose. Namely, animal 
model testing, by the implementation of new bioinformatics 
approaches, has shown that some existing drugs are effective 
in prolonging life expectancy48. Presently, this group of thera-
peutics includes, for example, multipurpose drug ruxolitinib, 
antineoplastic panobinostat, glucocorticoids, opioid loperamide, 
antipsychotic fluspirilen, antidiabetics metformin and acarbose, 
immunosuppressive drug sirolimus (rapamycin), tanespimy-
cin-analogue geldanamycin, antineoplastic antibiotics, polyphe-
nolic compound resveratrol etc.18, 48, 63, 77. According to present 
knowledge, it seems that tanespimycin has the greatest potential 
for senotherapeutic activity.
The process of discovering the senolytic or senomorphic poten-
tial of a compound in vitro and in vivo is a complex process that 
includes, for example, detailed knowledge of molecular-level 
mechanisms, cell / tissue types used in the study, senescence in-
duction method, knowledge of potential indirect effects on the 
immune system, etc.40. In order to reliably monitor the effects 
of potential senotherapeutics, special efforts are made to identify 
the specific markers of senescent cells and to optimize sensitive, 
precise and simple methods for their determination in biological 
samples (serum, plasma, lymphocytes, urine). According to the 
American Federation for Aging Research  (AFAR), the criteria 
to be met by aging markers are: to predict the rate of aging, to 
follow the basic aging process, to produce the test not harmful 
to the examinees and to be applicable in humans and animals78. 
Markers currently in use can generally be divided into molecular 
aging markers that may reflect molecular mechanisms of aging 
(eg. markes of DNA and chromosome, RNA and transcriptome, 
markers of oxidative stress, cell senescence, metabolism etc.) 
and phenotypic markers which are non-invasive and are easily 
available (eg. anthropometric features, body mass index, muscle 
mass, etc.)78.
There are several review articles that mention a greater number 
of aging markers, including cell senescence78, 79, 80, 81. For the 
time being, however, none of the markers does not meet the 
criteria of the ideal marker, and therefore, in principle, it is rec-
ommended to use marker panels. Accordingly, studies under the 
MARK-AGE project are under way to identify a set of markers 
that will best indicate the biological age of the person82. In sci-
entific research, the most commonly used is the determination 
of SAκ-galactosidase activity83, 84 and the method of shortening 
the telomeres85, 86.
concluSion
Although knowledge in the field of investigations of aging, 
particularly the role of cell senescence in the aging process of the 
organism, have been extended to the molecular level in recent 
years, it can be said that they are still almost at the very begin-
ning and far from complete understanding. In the future, many 
new discoveries are expected and an integrative approach will 
be needed for scientists from the fields of genetics, biology and 
evolution.
Can elimination of senescent cells be an intervention that will 
significantly extend human life? Detection and development 
of senotherapeutics is definitely a new and very promising field 
of drug research because today, along with traditional method-
ologies (eg. transgenic animals, in vivo models of illness etc.), 
various new technological approaches are available, such as 
sophisticated chemistry biology techniques, reporpose of already 
existing drugs, bioinformatics. Due to the numerous possible 
overlapping of the mechanisms of functioning, caution is re-
quired when interpreting their actions, selectivity and specificity 
and ultimately the efficacy of senotherapeutics. It should also 
be borne in mind that senescent cells, in addition to adverse 
effects, also have physiological functions, and that massively 
removing of such cells could disrupt the integrity of a tissue. 
For now, there are insufficient knowledge on the links between 
molecular, cellular and physiological aspects of the removal of 
senescent cells. Therefore, the question of whether the elimina-
tion of senescent cells can be effective in the extension of life 
span remains open. It is indisputable that the scientific field of 
aging testing and age-related diseases as well as the field of de-
velopment of senotherapeutics will further meet with numerous 
challenges.
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